Two GHRH (growth-hormone-releasing-hormone) analogs: tesamorelin — researched for visceral-fat outcomes and the one with an approved use — vs cjc-1295, the widely-studied research analog for growth-hormone pulse amplification. Here's a neutral, sourced side-by-side — no hype, every claim links to its evidence.
Also: Egrifta
Tesamorelin is an FDA-approved peptide (marketed as Egrifta) classified as a GHRH (Growth Hormone Releasing Hormone) analog. It is primarily used for reducing visceral fat and stimulating lipolysis (fat breakdown), specifically targeting HIV lipodystrophy.
Also: CJC-1295 with DAC, Modified GRF 1-29 (no DAC)
CJC-1295 is a chemical made in labs that acts like a tiny messenger in the body. It belongs to a group called peptides, which are small chains of building blocks.
| Tesamorelin | CJC-1295 | |
|---|---|---|
| Research status | Preclinical | Preclinical |
| Benefits documented | 195 | 176 |
| Research citations | 148 | 98 |
| Known side effects | 114 | 76 |
Top documented benefits — backed by research.
Key studies — click through to verify each on PubMed.
148 sourced studies
98 sourced studies
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.
Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects.
Once-daily administration of CJC-1295
Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse
Neither is a “winner” — they suit different goals. Compare the documented benefits and evidence above against what you’re actually trying to achieve, note the research status (approved vs research-stage), and read each full guide before deciding. Many people also stack peptides rather than pick one.
Source Tesamorelin
Source CJC-1295